PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-04-05

Date Title Company
05-Apr-2022 Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board Sanofi
05-Apr-2022 Synomics Achieves Key Milestone with Publication of First Peer Reviewed Study Synomics
05-Apr-2022 Two Day Virtual Seminar: Preventing Human Error in the Life Sciences Course, April 19-20, 2022 - ResearchAndMarkets.com Businesswire
05-Apr-2022 EIT Health calls on tech giants and corporates to back new initiative to address talent crunch in healthcare EIT Health
05-Apr-2022 New centre targets ‘undruggable’ cancers after major donation ICR
05-Apr-2022 Cytonus Therapeutics to Present Preclinical Data for Systemically Delivered Oncolytic Virus Program for Treating Metastatic Cancers at AACR 2022 Businesswire
05-Apr-2022 DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy Vifor Pharma
05-Apr-2022 FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis Regeneron
05-Apr-2022 Oxurion Announces Extraordinary and Annual Shareholders’ Meetings Oxurion
05-Apr-2022 AI test could predict effective cancer drug combinations in less than two days ICR
05-Apr-2022 Worldwide High Content Screening Industry to 2027 - Featuring Bio-Rad Laboratories, Biotek Instruments and Danaher Among Others - ResearchAndMarkets.com Businesswire
05-Apr-2022 AstraZeneca Announces Results from ETESIAN Phase IIb trial AstraZeneca
05-Apr-2022 Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting Bright Peak Therapeutics
05-Apr-2022 Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing safety and pharmacokinetics of second innovative formulation of 5-MeO-DMT Beckley Psytech
05-Apr-2022 Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy Medesis Pharma
05-Apr-2022 Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors Nouscom
05-Apr-2022 eTheRNA Announces Relocation and Expansion of R&D Facility eTheRNA immunotherapies NV
05-Apr-2022 In-person kick-off meeting of the Eurostars-funded REPRINT Asgard Therapeutics
05-Apr-2022 Versameb to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting Versameb
05-Apr-2022 MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Businesswire